AstraZeneca
Biopharmaceutical Manufacturer
Among the 1.3 billion hypertensive patients worldwide, nearly half are trapped in the dilemma of "ineffective medication" — the traditional antihypertensive drugs have targeted the RAAS system for over two decades without change, until today, a small molecule broke the deadlock! AstraZeneca announced the great success of the Phase III study of Baxdrostat, an oral drug that precisely targets aldosterone synthase, enabling the most difficult-to-treat resistant hypertension to achieve "double goals" for the first time: statistically significant and clinically meaningful. When Ozostat stumbled due to insufficient selectivity, how did Baxdrostat usher in a new era of blood pressure reduction with a hundredfold increase in precision?
Baxdrostat is a potential first-in-class, highly selective, potent oral small-molecule inhibitor targeting aldosterone synthase (ALDOS, encoded by the CYP11B2 gene). Its mechanism of action is revolutionary, directly targeting the last three steps of aldosterone synthesis. In the human body, aldosterone plays a key role in maintaining water and salt balance, but when aldosterone levels are disrupted, it can lead to elevated blood pressure. The renin-angiotensin-aldosterone system (RAAS) is a crucial system for regulating aldosterone levels, but most previous antihypertensive drugs primarily target the RAAS system with certain limitations. Baxdrostat breaks through the constraints of the RAAS system, acting directly on the critical steps of aldosterone synthesis, addressing the root cause of hypertension in approximately 25% of patients.
One of the major challenges in developing ALDOS inhibitors is controlling selectivity. The CYP11B2 gene shares a 93% sequence homology with the CYP11B1 gene, which encodes cortisol synthase. If a drug lacks selectivity, inhibiting aldosterone synthesis may also affect cortisol levels, leading to severe side effects. However, Baxdrostat has overcome this 93% homology challenge, achieving over 100-fold selective suppression of aldosterone synthase (ALDOS). While effectively reducing aldosterone levels, it does not impact cortisol levels, laying a solid foundation for its clinical application and establishing a robust technological moat.
Looking back at the first ALDOS inhibitor, osilodrostat, its lack of selectivity made it unable to effectively distinguish between aldosterone synthase and cortisol synthase. Its use affected cortisol levels, causing many adverse reactions. As a result, it could only be redirected for the treatment of Cushing's syndrome, failing to play a role in the field of hypertension treatment. In contrast, the high selectivity advantage of baxdrostat becomes even more prominent, bringing new hope to patients with hypertension and opening a new chapter in hypertension treatment.
For patients with hypertension, the situation where conventional drug treatments are not effective is troubling, especially for those with resistant hypertension. However, the Phase III clinical trial results of Baxdrostat have undoubtedly brought them a glimmer of hope.
The BaxHTN study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial that enrolled a total of 796 patients. These patients included those with hypertension who had received treatment with two different classes of antihypertensive drugs (one of which was a diuretic) but still had uncontrolled blood pressure, as well as patients with resistant hypertension who had been treated with three or more different classes of antihypertensive drugs (one of which was a diuretic).
The study results showed that at week 12 of treatment, the mean seated systolic blood pressure (SBP) in the Baxdrostat group was significantly reduced compared to the placebo group, both statistically and clinically. This indicates that Baxdrostat can effectively lower systolic blood pressure in patients with resistant hypertension and holds significant clinical application value.
In addition to the success of the primary endpoint, the study also successfully achieved all secondary endpoints. In the subgroup of patients with resistant hypertension, there was a significant improvement in SBP changes within 12 weeks; the change in seated diastolic blood pressure within 12 weeks also showed marked improvement in the overall population; and the proportion of patients achieving SBP <130mmHg at week 12 significantly increased. The success across all these secondary endpoints further demonstrates the efficacy and superiority of Baxdrostat in treating resistant hypertension.
In terms of safety, Baxdrostat also performs well, with overall good tolerability and safety. This is crucial for hypertensive patients who require long-term medication, as good safety means patients can better adhere to the treatment, thereby achieving better therapeutic outcomes.
On the promising track of ALDOS inhibitors, AstraZeneca, Mineralys, and Boehringer Ingelheim have emerged as the three major giants, engaging in fierce competition.
AstraZeneca's Baxdrostat Crosses the Finish Line First with Positive Results from the Phase III BaxHTN Study. The study successfully met its primary endpoint and all secondary endpoints, demonstrating good efficacy and safety, which gives it a competitive advantage. AstraZeneca plans to present detailed data from the study at the European Society of Cardiology (ESC) Congress in August 2025. This data will further solidify its competitive edge and development prospects in the market, playing a crucial role in its subsequent marketing and application.
Lorundrostat from Mineralys is also a formidable contender, demonstrating excellent performance in Phase III clinical trials, with the pivotal Phase III study completed in March this year. In vitro experimental data shows that Lorundrostat exhibits 374 times greater selectivity for ALDOS than for cortisol synthase, showing significant efficacy in treating uncontrolled and resistant hypertension. In the Launch-HTN trial, at week 6 of treatment, the Lorundrostat (50mg) group achieved an absolute reduction in systolic blood pressure of 16.9mmHg, with a placebo-adjusted value of -9.1mmHg (p<0.0001). At week 12 of treatment, patients in the Lorundrostat (50mg) group and the Lorundrostat (50-100mg) group achieved absolute reductions in systolic blood pressure of 19.0mmHg and 15.7mmHg respectively, with placebo-adjusted values of -11.7mmHg (p<0.0001) and -8.4mmHg (p=0.0016). These results indicate that Lorundrostat possesses potent antihypertensive capabilities and is a strong competitor to Baxdrostat.
BI690517 from Boehringer Ingelheim has chosen a different development path, not focusing on hypertension but concentrating on the treatment of heart failure and kidney disease. Although its competition in the field of hypertension treatment is relatively weak, it is expected to carve out new territory in the treatment of heart failure and kidney disease, providing patients with more treatment options.
From the perspective of market potential, the existing antihypertensive drug market is enormous. According to statistics, the global antihypertensive drug market has reached $50 billion. Among this, about 25% of hypertensive patients suffer from aldosterone dysregulation, indicating that there are over 300 million people globally with aldosterone imbalance. These individuals have an urgent need for new and effective therapeutic drugs, providing vast opportunities for the development of ALDOS inhibitor markets and becoming a highly sought-after target for pharmaceutical companies.
The emergence of Baxdrostat represents not only the birth of a new drug but also a significant shift in the treatment paradigm within the field of hypertension. Traditional antihypertensive drugs primarily target the RAAS system, lowering blood pressure by "plugging downstream leaks," such as angiotensin-converting enzyme inhibitors (ACEIs) that inhibit the conversion of angiotensin I to angiotensin II, and angiotensin II receptor blockers (ARBs) that block the binding of angiotensin II to its receptors. However, these drugs often show unsatisfactory effects on hypertension caused by dysregulated aldosterone levels.
Baxdrostat addresses the issue at its root by inhibiting aldosterone synthase, achieving "source interception" of aldosterone. This treatment method can more precisely target the critical pathogenic factor of aldosterone imbalance, providing patients with more effective therapy. Especially for patients with kidney damage or heart failure, the excessive secretion of aldosterone can further exacerbate the condition, and the application of Baxdrostat opens up a new therapeutic pathway for them, potentially slowing disease progression and improving patients' quality of life and survival rates.
In the real world, the treatment of hypertension faces many pain points. Among them, diuretic resistance and the situation where blood pressure cannot be effectively controlled even with the combination of multiple drugs are not uncommon. These clinical blind spots have been troubling doctors and patients. The emergence of Baxdrostat provides new possibilities for solving these problems. With its unique mechanism of action, it can break the dilemma of diuretic resistance, bringing hope to patients who respond poorly to traditional treatments, effectively controlling blood pressure, and reducing the risk of complications.
Looking Ahead: The Research and Application of Aldosterone Target Offer Vast Potential
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Click "Pharmacology" below to follow more exciting content.
Disclaimer
The push rules of WeChat Official Accounts have changed again. If you don't tap"Views"Or not set to"Star Mark", we might just dissipate in the vast sea of text~ Click here, don't miss out on the latest news from PharmaDJ!??